Success Metrics

Clinical Success Rate

93.8%

Based on 15 completed trials

Completion Rate

94%(15/16)

Active Trials

0(0%)

Results Posted

40%(6 trials)

Terminated

1(6%)

Phase Distribution

Ph not_applicable

12%

Ph phase_2

24%

Ph phase_4

41%

Ph phase_3

18%

Ph early_phase_1

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution17 total trials

Early Phase 1First-in-human

1(5.9%)

Phase 2Efficacy & side effects

4(23.5%)

Phase 3Large-scale testing

3(17.6%)

Phase 4Post-market surveillance

7(41.2%)

N/ANon-phased studies

2(11.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.8%

15 of 16 finished

Non-Completion Rate

6.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(15)

Terminated(1)

Other(1)

Detailed Status

Completed15

unknown1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

93.8%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (5.9%)

Phase 24 (23.5%)

Phase 33 (17.6%)

Phase 47 (41.2%)

N/A2 (11.8%)

Trials by Status

unknown16%

completed1588%

terminated16%

Recent Activity

0 active trials

Showing 5 of 17

completedphase_3

Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia

NCT05656027

completedphase_4

Clinical Trials (17)

Showing 17 of 17 trials

NCT05656027Phase 3

Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia

Completed

NCT06449352Phase 4

Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

Completed

NCT03959176Phase 4

The Effect of Brimonidine

Completed

NCT01144494Early Phase 1

Aqueous Humor Dynamics and Brimonidine

Mirvaso in Use Study

Dry Eye Disease Study With Brimonidine

Completed

NCT02289352Phase 3

Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea

Completed

NCT02761174Phase 4

Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias

Completed

NCT01726075Phase 2

Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy

Completed

NCT02140450Not Applicable

Effect of Antiglaucoma Agents on Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection

Completed

NCT01201551Not Applicable

Effect of Alphagan and Xalatan Eye Drops on Corneal Temperature

Completed

NCT00168363Phase 3

Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension

Completed

NCT01345448Phase 2

Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Brimonidine Therapy

Unknown

NCT00804921Phase 2

Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab

Completed

NCT00466479Phase 4

Brimonidine vs ALTP in Progressing Human Glaucoma

Completed

NCT00312416Phase 4

Effects of Topical Clonidine vs. Brimonidine on Choroidal Blood Flow and Intraocular Pressure During Isometric Exercise

Completed

NCT00347035Phase 4

INFLUENCE OF TOPICAL INDOMETHACIN ON HYPOTHENSIVE EFFECT OF BRIMONIDINE

Terminated

All 17 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 17